| Project/Area Number |
15K19162
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
Sakai Ryoko 東京女子医科大学, 医学部, 特任助教 (30631981)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 薬剤疫学 / 関節リウマチ / 分子標的薬 / 合併症 / 安全性 / 生物学的製剤 / 保険データベース / レジストリ |
|---|
| Outline of Final Research Achievements |
We compared the risk of hospitalized infection, herpes zoster (HZ), cardiovascular disease, stroke, and fracture between patients with and those without rheumatoid arthritis (RA) using the Japanese health insurance database. This study revealed for the first time in Japan that the RA group had significantly higher risks of these complications than the non-RA group did.
We investigated the incidence rate (IR) of HZ and associations between medications and HZ in patients with RA using the REAL database. The crude IR (95% confidence intervals) of HZ was 6.7 [4.9-8.8]/1,000 person-years. The adjusted odds ratios (ORs) of tumor necrosis factor inhibitor (TNFI) and oral corticosteroids dosage (per 1 mg prednisolone increment) were significantly elevated. The ORs of non-TNFI and methotrexate usage were not elevated.
|
